Beginning Cash: The amount of cash reported by the company on its previous statement.
Akari Therapeutics PLC (AKTX) had Beginning Cash of $2.66M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-17.30M |
|
-- |
|
-- |
|
$17.27M |
|
$-17.27M |
|
$-1.03M |
|
$-18.30M |
|
$-18.30M |
|
$-17.30M |
|
$-17.30M |
|
$-17.30M |
|
$-17.30M |
|
$-17.27M |
|
$-17.27M |
|
0.84M |
|
0.84M |
|
$-20.56 |
|
$-20.56 |
|
| Balance Sheet Financials | |
$5.46M |
|
-- |
|
$42.43M |
|
$47.89M |
|
$12.35M |
|
-- |
|
$7.21M |
|
$19.56M |
|
$28.33M |
|
$-14.10M |
|
$28.33M |
|
1.13M |
|
| Cash Flow Statement Financials | |
$-10.57M |
|
-- |
|
$13.17M |
|
|
Beginning Cash |
$2.66M |
$5.26M |
|
$2.60M |
|
$2.89M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.44 |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-61.06% |
|
122.66% |
|
-36.12% |
|
-61.06% |
|
$25.03 |
|
$-12.56 |
|
$-12.56 |
|